The DARE study of relapse prevention in depression: design for a phase 1/2 translational randomised controlled trial involving mindfulness-based cognitive therapy and supported self monitoring

BMC Psychiatry

Leon Piterman³  Zindel Segal¹  Paul R Martin²  Fiona Judd⁵  Graham N Meadows⁴  Frances Shawyer⁴ 

[1]Centre for Addiction and Mental Health, Clarke Division, Toronto, Ontario, Canada, M6B-2H8

[2]School of Applied Psychology, Griffith University, Mount Gravatt, Queensland, 4122, Australia

[3]Office of the Pro Vice Chancellor, (Berwick & Peninsula), Monash University, Narre Warren Victoria 3805, Australia

[4]School of Psychology and Psychiatry, Monash University, Clayton Victoria 3800, Australia

[5]Centre for Women's Mental Health, The Royal Women's Hospital, Parkville Victoria 3052 Australia

关键词: health economics;    translational research;    Major Depressive Disorder;    Mindfulness-Based Cognitive Therapy (MBCT);    Randomised controlled trial (RCT);   

Others  :  1124428
DOI  :  10.1186/1471-244X-12-3

 received in 2011-11-16, accepted in 2012-01-19,  发布年份 2012

【 摘 要 】

Background

Depression is a common condition that typically has a relapsing course. Effective interventions targeting relapse have the potential to dramatically reduce the point prevalence of the condition. Mindfulness-based cognitive therapy (MBCT) is a group-based intervention that has shown efficacy in reducing depressive relapse. While trials of MBCT to date have met the core requirements of phase 1 translational research, there is a need now to move to phase 2 translational research - the application of MBCT within real-world settings with a view to informing policy and clinical practice. The aim of this trial is to examine the clinical impact and health economics of MBCT under real-world conditions and where efforts have been made to assess for and prevent resentful demoralization among the control group. Secondary aims of the project involve extending the phase 1 agenda to an examination of the effects of co-morbidity and mechanisms of action.

Methods/Design

This study is designed as a prospective, multi-site, single-blind, randomised controlled trial using a group comparison design between involving the intervention, MBCT, and a self-monitoring comparison condition, Depression Relapse Active Monitoring (DRAM). Follow-up is over 2 years. The design of the study indicates recruitment from primary and secondary care of 204 participants who have a history of 3 or more episodes of Major Depression but who are currently well. Measures assessing depressive relapse/recurrence, time to first clinical intervention, treatment expectancy and a range of secondary outcomes and process variables are included. A health economics evaluation will be undertaken to assess the incremental cost of MBCT.

Discussion

The results of this trial, including an examination of clinical, functional and health economic outcomes, will be used to assess the role that this treatment approach may have in recommendations for treatment of depression in Australia and elsewhere. If the findings are positive, we expect that this research will consolidate the evidence base to guide the decision to fund MBCT and to seek to promote its availability to those who have experienced at least 3 episodes of depression.

【 授权许可】

   
2012 Shawyer et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Andrews G, Hall W, Teesson M, Henderson S: The Mental Health of Australians. Canberra: Commonwealth of Australia; 1999.
• [2]Slade T, Johnston A, Teesson M, Whiteford H, Burgess P, Pirkis J, Saw S: The Mental Health of Australians 2. Report on the 2007 National Survey of Mental Health and Wellbeing. Canberra: Commonwealth of Australia; 2009.
• [3]Lavori PW, Keller MB, Klerman GL: Relapse in affective disorders: a reanalysis of the literature using life table methods. Journal of Psychiatric Research 1984, 18(1):13-25.
• [4]Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT, Coryell W, Warshaw M, Turvey C, Maser JD, et al.: Multiple recurrences of major depressive disorder. American Journal of Psychiatry 2000, 157(2):229-233.
• [5]Patten SB: An animated depiction of major depression epidemiology. BMC Psychiatry 2007., 7(23)
• [6]Kabat-Zinn J: Full Catastrophe Living: Using the Wisdom of your Body and Mind to Face Stress, Pain and Illness. New York: Delacorte; 1990.
• [7]Chiesa A, Serretti A: Mindfulness based cognitive therapy for psychiatric disorders: a systematic review and meta-analysis. Psychiatry Research 2011, 187:441-453.
• [8]National Collaborating Centre for Mental Health: Depression: The Treatment and Management of Depression in Adults. London: National Institute for Health and Clinical Excellence; 2009.
• [9]Lean MEJ, Mann JI, Hoek JA, Elliot RM, Schofield G: Translational research: from evidence based medicine to sustainable solutions for public health problems. British Medical Journal 2008, 337:705-706.
• [10]Del Mar C: Is primary care research a lost cause? British Medical Journal 2010, 340:61-62.
• [11]Teasdale JD, Segal ZV, Williams JMG, Ridgeway VA, Soulsby JM, Lau MA: Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Journal of Consulting & Clinical Psychology 2000, 68(4):615-623.
• [12]Ma SH, Teasdale JD: Mindfulness-based cognitive therapy for depression: replication and exploration of differential relapse prevention effects. Journal of Consulting & Clinical Psychology 2004, 72(1):31-40.
• [13]Bondolfi G, Jermann F, Van der Linden M, Gex-Fabry M, Bizzini L, Rouget BW, Myers-Arrazola L, Gonzalez C, Segal ZV, Aubry J, et al.: Depression relapse prophylaxis with Mindfulness-Based Cognitive Therapy: replication and extension in the Swiss health care system. Journal of Affective Disorders 2010, 122:224-231.
• [14]Kuyken W, Byford S, Taylor RS, Watkins E, Holden E, White K, Barrett B, Byng R, Evans A, Mullan E, et al.: Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. Journal of Consulting and Clinical Psychology 2008, 76(6):966-978.
• [15]Segal ZV, Bieling P, Young T, MacQueen G, Cooke R, Martin L, Block R, Levitan RD: Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression. Archives of General Psychiatry 2010, 67(12):1256-1264.
• [16]Godfrin KA, van Heeringen C: The effects of mindfulness-based cognitive therapy on recurrence of depressive episodes, mental health and quality of life: a randomized controlled study. Behaviour Research and Therapy 2010, 48:738-746.
• [17]Stufflebeam DL: CIPP Evaluation Model Checklist. Second edition. Kalamazoo, MI Western Michigan University; 2007.
• [18]Bieling P: Is it medication or mindfulness in prevention of depressive relapse? Neuropsychiatry 2011, 1(2):97-99.
• [19]Ellis P: Australian and New Zealand clinical practice guidelines for the treatment of depression. Australian and New Zealand Journal of Psychiatry 2004, 38:389-407.
• [20]Mathew KL, Whitford HS, Kenny MA, Denson LA: The long-term effects of mindfulness-based cognitive therapy as a relapse prevention treatment for major depressive disorder. Behavioural and Cognitive Psychotherapy 2010, 38:561-576.
• [21]Mueller TI, Leon AC, Keller MB: Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. American Journal of Psychiatry 1999, 15:1000-1006.
• [22]Kingston T, Bates A, Dooley B, Lawlor E, Malone K: Mindfulness-based cognitive therapy for residual depressive symptoms. Psychology and Psychotherapy: Theory, Research, and Practice 2007, 80(2):193-203.
• [23]Michalak J, Heidenreich T, Meibert P, Schulte D: Mindfulness predicts relapse/recurrence in major depressive disorder after mindfulness-based cognitive therapy. The Journal of Nervous and Mental Disease 2008, 196(8):630-633.
• [24]Shahar B, Britton WB, Sbarra DA, Figueredo AJ, Bootzin RR: Mechanisms of change in mindfulness-based cognitive therapy for depression: preliminary evidence from a randomized controlled trial. International Journal of Cognitive Therapy 2010, 3(4):402-418.
• [25]Speca M, Carlson LE, Goodey E, Angen M: A randomized, wait-list controlled clinical trial: The effect of a mindfulness meditation-based stress reduction program on mood and symptoms of stress in cancer outpatients. Psychosomatic Medicine 2000, 62(5):613-622.
• [26]Kuyken W, Watkins E, Holden E, White K, Taylor R, Byford S, Evans A, Radford S, Teasdale JD, Dalgleish T: How does mindfulness-based cognitive therapy work? Behaviour Research and Therapy 2010, 48:1105-1112.
• [27]Hirschfeld RMA: The comorbidity of major depression and anxiety disorders: recognition and management in primary care. The Primary Care Companion to the Journal of Clinical Psychiatry 2001, 3(6):244-254.
• [28]Segal ZV, Williams JMG, Teasdale J: Mindfulness-Based Cognitive Therapy for Depression: A New Approach to Preventing Relapse. New York: Guilford; 2002.
• [29]Ramel W, Goldin PR, Carmona PE, McQuaid JR: The effects of mindfulness meditation on cognitive processes and affect in patients with past depression. Cognitive Therapy and Research 2004, 28(4):433-455.
• [30]Hofmann SG, Sawyer AT, Witt AA, Oh D: The effect of mindfulness-based therapy on anxiety and depression: a meta-analytic review. Journal of Consulting and Clinical Psychology 2010, 78(2):169-183.
• [31]Coelho HF, Canter PH, Ernst E: Mindfulness-based cognitive therapy: evaluating current evidence and informing future research. Journal of Consulting and Clinical Psychology 2007, 75(6):1000-1005.
• [32]Everitt BS, Wessely S: Clinical Trials in Psychiatry. Oxford: Oxford University Press; 2004.
• [33]Pilcher H: The science of voodoo: when mind attacks body. New Scientist 2009, 202(2708):30-33. New Scientist, 2708, 5
• [34]Segal ZV, Teasdale JD, Williams JMG, Gemar MC: The Mindfulness-Based Cognitive Therapy Adherence Scale: inter-rater reliability, adherence to protocol and treatment distinctiveness. Clinical Psychology and Psychotherapy 2002, 9:131-138.
• [35]Montgomery SA, Dufour H, Brion S, Gailledreau J, Laqueille X, Ferrey G, Moron P, Parant-Lucena N, Singer L, Danion JM, et al.: The prophylactic efficacy of fluoxetine in unipolar depression. British Journal of Psychiatry 1988, 153(Suppl 3):69-76.
• [36]Montgomery SA, Evans R: Relapse prevention with antidepressants. Nordic Journal of Psychiatry 1993, 47(Suppl 30):83-88.
• [37]Rouillon F, Berdeaux G, Bisserbe JC, Warner B, Mesbah M, Smadja C, Chwalow J: Prevention of recurrent depressive episodes with milnacipran: consequences on quality of life. Journal of Affective Disorders 2000, 58(3):171-180.
• [38]Terra JL, Montgomery SA: Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. International Clinical Psychopharmacology 1998, 13(2):55-62.
• [39]Stata Statistical Software; Panel data/cross-sectional time series - Version 9 [http://www.stata.com/capabilities/panel.html] webcite
• [40]Thase ME, Greenhouse JB, Frank E, Reynolds CF, Pilkonis PA, Hurley K, Grochocinski V, Kupfer DJ: Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Archives of General Psychiatry 1997, 54:1009-1015.
• [41]Dupont WD, Plummer WD: Power and sample size calculations: a review and computer program. Controlled Clinical Trials 1990, 11:116-128.
• [42]Evans S, Royston P, Day S: [http://www-users.york.ac.uk/~mb55/guide/minim.htm] webciteMinim: allocation by minimisation in clinical trials. London: St George's Medical School; 2001.
• [43]Jordanova V, Wickramesinghe C, Gerada C, Prince M: Validation of two survey diagnostic interviews among primary care attendees: a comparison of CIS-R and CIDI with SCAN ICD-10 diagnostic categories. Psychological Medicine 2004, 34(6):1013-1024.
• [44]Kessler RC, Abelson J, Demler O, Escobar JI, Gibbon M, Guyer ME, Howes MJ, Jin R, Vega WA, Walters EE, et al.: Clinical calibration of DSM-IV diagnoses in the World Mental Health (WMH) Version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). International Journal of Methods in Psychiatric Research 2004, 13(2):122-139.
• [45]Kroenke K, Spitzer RL, Williams JBW: The Patient Health Questionnaire-2: validity of a two-item depression screener. Medical Care 2003, 41(11):1284-1292.
• [46]Kroenke K, Spitzer RL, Williams JBW: The PHQ-9. Validity of a brief depression severity measure. Journal of General Internal Medicine 2001, 16:606-613.
• [47]McNab C, Meadows G: The General-practice Users' Perceived-need Inventory ('GUPI'): a brief general practice tool to assist in bringing mental healthcare needs to professional attention. Primary Care Mental Health 2005, 3:93-101.
• [48]Devilly GJ, Borkovec TD: Psychometric properties of the credibility/expectancy questionnaire. Journal of Behavior Therapy & Experimental Psychiatry 2000, 31(2):73-86.
• [49]Spielberger CD: Manual for the State-Trait Anxiety Inventory (STAI). Palo Alto, CA: Consulting Psychologists Press; 1983.
• [50]Goldberg LR: A broad-bandwidth, public domain, personality inventory measuring the lower-level facets of several five-factor models. In Personality Psychology in Europe. Volume 7. Edited by Mervielde I, Deary I, De Fruyt F, Ostendorf F. Tilburg: Tilburg University Press; 1999::7-28.
• [51]Goldberg LR, Johnson JA, Eber HW, Hogan R, Ashton MC, Cloninger R, Gough HG: The international personality item pool and the future of public-domain personality measures. Journal of Research in Personality 2006, 40:84-96.
• [52]Baer RA, Smith GT, Hopkins J, Krietemeyer J, Toney L: Using self-report assessment methods to explore facets of mindfulness. Assessment 2006, 13(1):27-45.
• [53]Nolen-Hoeksema S, Morrow J: A prospective study of depression and posttraumatic stress symptoms after a natural disaster: the 1989 Loma Prieta earthquake. Journal of Personality and Social Psychology 1991, 61(1):115-121.
• [54]Kim TM, Hill MN, Bone LR, Levine DM: Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale. Progress in Cardiovascular Nursing 2000, 15(3):90-96.
• [55]Mundt JC, Marks IM, Shear MK: The work and social adjustment scale: a simple measure of impairment in functioning. British Journal of Psychiatry 2002, 180:461-464.
• [56]Hawthorne G, Richardson J, Osborne R: The Assessment of Quality of Life (AQoL) instrument: A psychometric measure of health-related quality of life. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care & Rehabilitation 1999, 8(3):209-224.
• [57]Mihalopoulos C, Meadows G, Stiller A, Pirkis J, Burgess P: Attatching unit costs to Australia's National Survey of Mental Health and Wellbeing. Journal of Mental Health Policy and Economics 2005, 8:61-69.
• [58]Meadows G, Burgess P, Fossey E, Harvey C: Perceived need for mental health care, findings from the Australian National Survey of Mental Health and Wellbeing. Psychological Medicine 2000, 30:645-656.
• [59]Meadows G, Harvey C, Fossey E, Burgess P: Assessing perceived need for mental health care in a community survey: development of the Perceived Need for Care Questionnaire. Social Psychiatry and Psychiatric Epidemiology 2000, 35:427-435.
• [60]Meadows G, Liaw T, Burgess P, Bobevski I, Fossey E: Australian general practice and the meeting of needs for mental health care. Social Psychiatry & Psychiatric Epidemiology 2001, 36(12):595-603.
• [61]Trewin D, Pink B: ANZSCO - Australian and New Zealand Standard Classification of Occupations. Belconnen, ACT: Australian Bureau of Statistics; 2006.
• [62]Meadows G, Byrne MK, Cichello A, Favilla A, Feros D, Graham A, McNab C, Milton I, Mitchell P, Sharples B, et al.: [http:/ / www.med.monash.edu.au/ spppm/ research/ southernsynergy/ download/ mima_report_final_2010.pdf] webcitePreventing Relapse in Depression: The Mindfulness-Based Cognitive Therapy and Medication Alliance Therapy Project: Final Report. Southern Synergy, Monash University; 2010.
• [63]Milton I, Sharples B: MBCT-OZ: Lesson Plans for Australia. Melbourne: School of Psychology, Psychiatry, and Psychological Medicine, Monash University; 2010.
• [64]Baron RM, Kenny DA: The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. Journal of Personality and Social Psychology 1986, 51:1173-1182.
• [65]Preacher KJ, Hayes AF: Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behavior Research Methods 2008, 40(3):879-891.
• [66]Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, Brazier J, O'Hagan T: Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Economics 2005, 14:339-347.
• [67]Fenwick E, Claxton K, Sculpher M: Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Economics 2001, 10:779-787.
• [68]Hollis S, Campbell F: What is meant by intention to treat analysis? Survey of published randomised controlled trials. British Medical Journal 1999, 319:670-674.
• [69]Leyland AH, Goldstein H (Eds): Multilevel Modelling of Health Statistics. Chichester: John Wiley & Sons, Ltd; 2001.
• [70]Hjelmgren J, Berggren F, Andersson F: Health economic guidelines - similarities, differences and some implications. Value in Health 2001, 4(3):225-250.
• [71]Williams JMG, Russell IT, Crane C, Russell D, Whitaker CJ, Duggan DS, Barnhofer T, Fennell M, Crane R, Silverton S: Staying well after depression: trial design and protocol. BMC Psychiatry 2010., 10(23)
• [72]Ludman E, Katon W, Bush T, Rutter C, Lin E, Simon G, Von Korff M, Walker E: Behavioural factors associated with symptom outcomes in a primary care-based depression prevention intervention trial. Psychological Medicine 2003, 33:1061-1070.
• [73]McCabe Ruff K, Mackenzie ER: The role of mindfulness in healthcare reform: a policy paper. Explore 2009, 5(6):313-323.